Scientific database and research platform CiteAb announced on Monday the launch of its CiteAb Explore Platform, comprising the Reagent Search Engine and new Image Search Engine.
Built on over a decade of AI-driven data collection combined with expert human curation, CiteAb's database contains 16 million research tools and their use in 40 million publications, covering antibodies, proteins, models, kits and more. As of 2026, instrument data is also included. This data underpins the Explore Platform, which helps researchers identify fit-for-purpose reagents, faster.
The new Image Search tool is designed to enable researchers to rapidly investigate peer-reviewed scientific images. Developed with input from the scientific community, it provides easy access to 850,000 cropped experimental images -- covering 610,000 proteins, 5,000 diseases, and 160,000 cell lines -- linked directly to publications and the reagents used.
Together, the research tools in CiteAb Explore are intended to help researchers cut time spent navigating fragmented data sources, reduce R&D waste, and achieve more reproducible results.
The CiteAb Explore platform is freely accessible to academics, with a paid subscription model for commercial users.
Natera to support Phase 1 trial of Kupando's immunotherapy in advanced skin cancers
Laekna's New Drug Application for LAE002 (afuresertib) accepted by China's NMPA
AcuCort publishes Phase IV study results on patient use of Zeqmelit oral film
SoftOx doses first patient in SIS-03 proof-of-concept trial
BSF secures exclusive global commercialisation partnership for ETSYL
Aureka Biotechnologies raises USD100m to build biological world model for drug discovery
AbCellera reports positive Phase 2 results for menopause treatment ABCL635
Bristol Myers Squibb to invest USD2.3bn in Houston manufacturing campus
BeOne Medicines and Revolution Medicines expand oncology collaboration
Almirall partners with CrystalO to develop small molecules for medical dermatology
Sobi partners with Innate Pharma to advance lacutamab in T-cell lymphoma
Saniona grants AstronauTx worldwide rights to neurological disease programme